Advances in Diabetes Pharmacotherapy: An Update for the Emergency Provider.
Advances in Diabetes Pharmacotherapy: An Update for the Emergency Provider.
- 2018
Available online from MWHC library: 1995 - present, Available in print through MWHC library:1999-2007
BACKGROUND: Diabetes mellitus is a disease that affects millions of Americans, and its prevalence is only anticipated to increase in coming years. It is estimated that diabetes-related visits account for 1% of all emergency department (ED) encounters. In recent years, there have been several new categories of medications approved for the treatment of diabetes, including new insulins, glucagon-like peptide-1 receptor agonists, dipeptidyl peptidase-4 inhibitors, an amylin analogue, and sodium-glucose cotransporter-2 inhibitors. CONCLUSIONS: Emergency providers will encounter patients taking these newly approved medications, as well as treat those presenting with adverse effects and overdoses from them. As such, emergency providers must have a basic understanding of these new therapies so that they can optimally care for diabetic patients. Copyright (c) 2017 Elsevier Inc. All rights reserved. DISCUSSION: Many of these new therapies have been incorporated as first- and second-line agents for the management of diabetes. Recently approved diabetes medications often have different mechanisms of action and adverse effect and overdose profiles compared to traditional agents, such as sulfonylureas and metformin. OBJECTIVE OF THE REVIEW: This review presents recently approved agents to treat diabetes, with a focus on basic mechanism, place in therapy, and toxicities the ED provider may encounter.
English
0736-4679
*Diabetes Mellitus/dt [Drug Therapy]
*Drug Therapy/td [Trends]
*Emergency Medicine/td [Trends]
Dipeptidyl Peptidase 4/ag [Agonists]
Dipeptidyl Peptidase 4/tu [Therapeutic Use]
Glucagon-Like Peptide-1 Receptor/ai [Antagonists & Inhibitors]
Glucagon-Like Peptide-1 Receptor/tu [Therapeutic Use]
Humans
Insulin Glargine/pd [Pharmacology]
Insulin Glargine/tu [Therapeutic Use]
Insulin, Long-Acting/pd [Pharmacology]
Insulin, Long-Acting/tu [Therapeutic Use]
Islet Amyloid Polypeptide/an [Analysis]
Islet Amyloid Polypeptide/tu [Therapeutic Use]
Sodium-Glucose Transporter 2/ai [Antagonists & Inhibitors]
Sodium-Glucose Transporter 2/tu [Therapeutic Use]
MedStar Washington Hospital Center
Emergency Medicine
Journal Article
Available online from MWHC library: 1995 - present, Available in print through MWHC library:1999-2007
BACKGROUND: Diabetes mellitus is a disease that affects millions of Americans, and its prevalence is only anticipated to increase in coming years. It is estimated that diabetes-related visits account for 1% of all emergency department (ED) encounters. In recent years, there have been several new categories of medications approved for the treatment of diabetes, including new insulins, glucagon-like peptide-1 receptor agonists, dipeptidyl peptidase-4 inhibitors, an amylin analogue, and sodium-glucose cotransporter-2 inhibitors. CONCLUSIONS: Emergency providers will encounter patients taking these newly approved medications, as well as treat those presenting with adverse effects and overdoses from them. As such, emergency providers must have a basic understanding of these new therapies so that they can optimally care for diabetic patients. Copyright (c) 2017 Elsevier Inc. All rights reserved. DISCUSSION: Many of these new therapies have been incorporated as first- and second-line agents for the management of diabetes. Recently approved diabetes medications often have different mechanisms of action and adverse effect and overdose profiles compared to traditional agents, such as sulfonylureas and metformin. OBJECTIVE OF THE REVIEW: This review presents recently approved agents to treat diabetes, with a focus on basic mechanism, place in therapy, and toxicities the ED provider may encounter.
English
0736-4679
*Diabetes Mellitus/dt [Drug Therapy]
*Drug Therapy/td [Trends]
*Emergency Medicine/td [Trends]
Dipeptidyl Peptidase 4/ag [Agonists]
Dipeptidyl Peptidase 4/tu [Therapeutic Use]
Glucagon-Like Peptide-1 Receptor/ai [Antagonists & Inhibitors]
Glucagon-Like Peptide-1 Receptor/tu [Therapeutic Use]
Humans
Insulin Glargine/pd [Pharmacology]
Insulin Glargine/tu [Therapeutic Use]
Insulin, Long-Acting/pd [Pharmacology]
Insulin, Long-Acting/tu [Therapeutic Use]
Islet Amyloid Polypeptide/an [Analysis]
Islet Amyloid Polypeptide/tu [Therapeutic Use]
Sodium-Glucose Transporter 2/ai [Antagonists & Inhibitors]
Sodium-Glucose Transporter 2/tu [Therapeutic Use]
MedStar Washington Hospital Center
Emergency Medicine
Journal Article